TANs are considered a major source of growth factors involved in tumor angiogenesis, and their infiltration has been associated with resistance to antivascular endothelial growth factor (VEGF) therapy.29 The anti-VEGF and anti-angiopoietin-2 bispecific antibody venucizumab has been evaluated in a phase I clinical trial in combination with atezolizumab (anti-PD-L1 antibody) in patients with advanced cancer with acceptable safety profile and promising effect on tumor angiogenesis and cellular density were observed (NCT01688206). The gene discussed is ANGPT2; the disease is neoplasm.